This provided the foundation for the ECHELON-2 study, a double-blinded, double-dummy, multicenter, phase III trial directly comparing BV + CHP every three weeks for 6–8 cycles (n = 226) head-to-head with CHOP every three weeks for 6–8 cycles (n = 226) in previously untreated PTCL with CD30+ expression >10%. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.